139,270 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Bought by Nicholas Investment Partners LP

Posted by George Bondi on Aug 25th, 2026

Nicholas Investment Partners LP bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 139,270 shares of the company’s stock, valued at approximately $15,463,000.

Several other large investors also recently bought and sold shares of RYTM. Legal & General Group Plc acquired a new position in shares of Rhythm Pharmaceuticals during the 2nd quarter worth $4,875,000. The Manufacturers Life Insurance Company acquired a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at about $6,348,000. Nan Fung Group Holdings Ltd acquired a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at about $5,453,794,000. Algert Global LLC increased its holdings in Rhythm Pharmaceuticals by 42.6% during the 2nd quarter. Algert Global LLC now owns 83,431 shares of the company’s stock valued at $9,263,000 after acquiring an additional 24,918 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter valued at about $15,085,000.

Insider Activity

In other news, insider Joseph Shulman sold 5,079 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $119.75, for a total transaction of $608,210.25. Following the completion of the sale, the insider directly owned 15,915 shares of the company’s stock, valued at $1,905,821.25. The trade was a 24.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jennifer Kayden Lee sold 75,834 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $117.38, for a total transaction of $8,901,394.92. Following the sale, the executive vice president directly owned 54,233 shares of the company’s stock, valued at $6,365,869.54. This represents a 58.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 182,676 shares of company stock valued at $20,754,691 in the last ninety days. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on RYTM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Citigroup reiterated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their price target on Rhythm Pharmaceuticals from $145.00 to $146.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Canaccord Genuity Group set a $154.00 price objective on Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $142.44.

Read Our Latest Research Report on Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Price Performance

RYTM opened at $111.44 on Tuesday. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of -35.83 and a beta of 1.92. The business has a 50-day moving average of $108.47 and a two-hundred day moving average of $96.72. Rhythm Pharmaceuticals, Inc. has a 12 month low of $74.50 and a 12 month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.08. Rhythm Pharmaceuticals had a negative net margin of 85.59% and a negative return on equity of 159.87%. The business had revenue of $71.25 million for the quarter, compared to analysts’ expectations of $67.66 million. During the same period last year, the company earned ($0.75) earnings per share. The company’s quarterly revenue was up 46.9% on a year-over-year basis. Equities research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -2.82 earnings per share for the current year.

About Rhythm Pharmaceuticals

(Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.